[Efficacy of percutaneous caffeine in the treatment of apnea in the premature infant].
In 18 prematures (gestational age less than 32 weeks), an aqueous monohydrated caffeine colloidal gel was administered topically. High plasma levels were rapidly obtained with a loading dose divided in 4 applications by massaging, 1 ml of gel per kg body weight, at 12 hour intervals (18 mg caffeine base/kg). Maintenance was then instituted with a dose of 0.5 ml/kg/day. Treatment was initiated before 8 days of life, in children under assisted ventilation but without severe pulmonary involvement, during the period of weaning from the respirator. A good local and general tolerance was invariably observed and remarkable therapeutic efficacy was obtained.
Morisot
C
C
Service de Néonatologie, Hôpital Calmette, Centre Hospitalier Universitaire, Lille.
Simoens
C
C
Trublin
F
F
Lhermitte
M
M
Gremillet
C
C
Robert
M H
MH
Lequien
P
P
D000279:Administration, Cutaneous; D001049:Apnea / Q000188:drug therapy* / Q000517:prevention & control; D002110:Caffeine / Q000008:administration & dosage / Q000097:blood / Q000627:therapeutic use*; D006801:Humans; D007231:Infant, Newborn; D007235:Infant, Premature, Diseases / Q000188:drug therapy*; D008405:Massage
D002110:Caffeine
Efficacité de la caféine transcutanée dans le traitement des apnées du prématuré.